|Title||The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study.|
|Publication Type||Journal Article|
|Year of Publication||2021|
|Authors||Conley, BA, Staudt, L, Takebe, N, Wheeler, DA, Wang, L, Cardenas, MF, Korchina, V, Zenklusen, JClaude, McShane, LM, Tricoli, JV, Williams, PM, Lubensky, I, O'Sullivan-Coyne, G, Kohn, E, Little, RF, White, J, Malik, S, Harris, LN, Mann, B, Weil, C, Tarnuzzer, R, Karlovich, C, Rodgers, B, Shankar, L, Jacobs, PM, Nolan, T, Berryman, SM, Gastier-Foster, J, Bowen, J, Leraas, K, Shen, H, Laird, PW, Esteller, M, Miller, V, Johnson, A, Edmondson, EF, Giordano, TJ, Kim, B, S Ivy, P|
|Journal||J Natl Cancer Inst|
|Date Published||2021 Jan 04|
|Keywords||Adult, Aged, Aged, 80 and over, Exome Sequencing, Feasibility Studies, Female, High-Throughput Nucleotide Sequencing, Humans, Male, Middle Aged, Mutation, National Cancer Institute (U.S.), Neoplasms, Pilot Projects, Precision Medicine, Retrospective Studies, Sequence Analysis, RNA, Transcriptome, United States|
BACKGROUND: Tumor molecular profiling from patients experiencing exceptional responses to systemic therapy may provide insights into cancer biology and improve treatment tailoring. This pilot study evaluates the feasibility of identifying exceptional responders retrospectively, obtaining pre-exceptional response treatment tumor tissues, and analyzing them with state-of-the-art molecular analysis tools to identify potential molecular explanations for responses.
METHODS: Exceptional response was defined as partial (PR) or complete (CR) response to a systemic treatment with population PR or CR rate less than 10% or an unusually long response (eg, duration >3 times published median). Cases proposed by patients' clinicians were reviewed by clinical and translational experts. Tumor and normal tissue (if possible) were profiled with whole exome sequencing and, if possible, targeted deep sequencing, RNA sequencing, methylation arrays, and immunohistochemistry. Potential germline mutations were tracked for relevance to disease.
RESULTS: Cases reflected a variety of tumors and standard and investigational treatments. Of 520 cases, 476 (91.5%) were accepted for further review, and 222 of 476 (46.6%) proposed cases met requirements as exceptional responders. Clinical data were obtained from 168 of 222 cases (75.7%). Tumor was provided from 130 of 168 cases (77.4%). Of 117 of the 130 (90.0%) cases with sufficient nucleic acids, 109 (93.2%) were successfully analyzed; 6 patients had potentially actionable germline mutations.
CONCLUSION: Exceptional responses occur with standard and investigational treatment. Retrospective identification of exceptional responders, accessioning, and sequencing of pretreatment archived tissue is feasible. Data from molecular analyses of tumors, particularly when combining results from patients who received similar treatments, may elucidate molecular bases for exceptional responses.
|Alternate Journal||J Natl Cancer Inst|
|PubMed Central ID||PMC7781457|
|Grant List||U24 CA210969 / CA / NCI NIH HHS / United States |
U24 CA264023 / CA / NCI NIH HHS / United States
The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study.
|Deleterious heteroplasmic mitochondrial mutations are associated with an increased risk of overall and cancer-specific mortality. Nat Commun. 2023;14(1):6113..|
|PLS3 missense variants affecting the actin-binding domains cause X-linked congenital diaphragmatic hernia and body-wall defects. Am J Hum Genet. 2023;110(10):1787-1803..|
|Chimeric RNAs reveal putative neoantigen peptides for developing tumor vaccines for breast cancer. Front Immunol. 2023;14:1188831..|